Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma
NCT05099848Phase 2Completed
- Sponsor
- Shandong Cancer Hospital
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in hepatocellular carcinoma (HCC), sponsored by Shandong Cancer Hospital. Primary endpoints: R0 resection rate and Surgical conversion rate. Started Mar 2021; status: completed.
02
Drugs
camrelizumabRivoceranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05099848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05099848.